Impax Laboratories, Inc. (IPXL) Expected to Post Quarterly Sales of $198.42 Million
Equities analysts forecast that Impax Laboratories, Inc. (NASDAQ:IPXL) will report $198.42 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Impax Laboratories’ earnings, with the highest sales estimate coming in at $204.30 million and the lowest estimate coming in at $192.52 million. Impax Laboratories also posted sales of $198.42 million during the same quarter last year. The company is scheduled to issue its next earnings results on Wednesday, March 7th.
According to Zacks, analysts expect that Impax Laboratories will report full-year sales of $198.42 million for the current year, with estimates ranging from $773.61 million to $810.00 million. For the next fiscal year, analysts anticipate that the company will report sales of $843.92 million per share, with estimates ranging from $797.70 million to $881.48 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Impax Laboratories.
Impax Laboratories (NASDAQ:IPXL) last announced its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.03. Impax Laboratories had a negative return on equity of 39.31% and a negative net margin of 23.92%. The firm had revenue of $206.40 million for the quarter, compared to analysts’ expectations of $208.38 million. During the same quarter in the previous year, the company earned $0.37 earnings per share. The firm’s quarterly revenue was down 9.4% compared to the same quarter last year.
Several equities research analysts recently commented on the company. Canaccord Genuity set a $19.00 target price on Impax Laboratories and gave the stock a “hold” rating in a report on Wednesday, August 9th. UBS AG boosted their target price on Impax Laboratories from $12.00 to $16.00 and gave the stock a “sell” rating in a report on Monday, October 30th. Cantor Fitzgerald set a $20.00 price target on Impax Laboratories and gave the company a “buy” rating in a report on Wednesday, August 9th. Citigroup Inc. upped their price target on Impax Laboratories to $23.00 and gave the company a “buy” rating in a report on Tuesday, September 19th. Finally, Zacks Investment Research cut Impax Laboratories from a “hold” rating to a “strong sell” rating in a report on Monday, July 24th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the stock. Impax Laboratories currently has a consensus rating of “Hold” and a consensus target price of $19.60.
COPYRIGHT VIOLATION NOTICE: “Impax Laboratories, Inc. (IPXL) Expected to Post Quarterly Sales of $198.42 Million” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/11/18/impax-laboratories-inc-ipxl-expected-to-post-quarterly-sales-of-198-42-million.html.
Shares of Impax Laboratories (NASDAQ IPXL) traded down $0.07 during trading hours on Wednesday, reaching $16.60. The company had a trading volume of 946,913 shares, compared to its average volume of 1,970,000. Impax Laboratories has a 1 year low of $7.75 and a 1 year high of $25.70. The company has a market capitalization of $1,230.00, a PE ratio of 25.26, a price-to-earnings-growth ratio of 1.08 and a beta of 0.99. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.32 and a current ratio of 1.81.
Several institutional investors have recently bought and sold shares of the company. FMR LLC boosted its holdings in Impax Laboratories by 23.7% in the first quarter. FMR LLC now owns 498,500 shares of the specialty pharmaceutical company’s stock worth $6,306,000 after purchasing an additional 95,432 shares in the last quarter. Teachers Advisors LLC boosted its holdings in Impax Laboratories by 1.7% in the first quarter. Teachers Advisors LLC now owns 122,785 shares of the specialty pharmaceutical company’s stock worth $1,553,000 after purchasing an additional 2,073 shares in the last quarter. Legal & General Group Plc boosted its holdings in Impax Laboratories by 0.5% in the first quarter. Legal & General Group Plc now owns 131,834 shares of the specialty pharmaceutical company’s stock worth $1,668,000 after purchasing an additional 610 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Impax Laboratories by 4.6% in the first quarter. Vanguard Group Inc. now owns 6,251,395 shares of the specialty pharmaceutical company’s stock worth $79,080,000 after purchasing an additional 276,765 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Impax Laboratories by 47.2% in the first quarter. Dimensional Fund Advisors LP now owns 2,637,077 shares of the specialty pharmaceutical company’s stock worth $33,359,000 after purchasing an additional 845,375 shares in the last quarter. Institutional investors and hedge funds own 88.32% of the company’s stock.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related stocks with our FREE daily email newsletter.